Navamedic (NAVA) M&A Announcement summary

Deal rationale and strategic fit

• Acquisition expands presence in addiction treatment, a fast-growing therapeutic area with significant societal impact and aligns with the mission to deliver high-quality, needed products.

• Strengthens position as a leading Nordic provider in specialty pharma, supporting long-term growth and public health objectives.

• Product portfolio complements existing logistics, warehousing, and market expansion plans, enabling rapid access across Nordics and Europe.

• Supports ambition to increase portfolio of fully owned, specialized products.

Financial terms and conditions

• Total consideration up to NOK 225 million: NOK 185 million at closing, NOK 40 million contingent on sales milestones.

• Funded by NOK 110 million loan and NOK 110–130 million rights issue, underwritten by the largest shareholder.

• Rights issue subscription price set at NOK 21.50 per share.

• 2024 net sales of acquired business were NOK 62 million; expected to contribute to NOK 1 billion revenue target.

• Closing expected July 15th, 2025, conditional on EGM approval on July 14th, with rights issue to follow and complete by early October.

Synergies and expected cost savings

• Integration into existing commercial platform expected to yield significant synergies in logistics, warehousing, and tender management.

• Anticipated annualized EBITDA contribution of NOK 25 million post-integration, with potential for further growth.

• Cost synergies, especially from reduced overhead, expected to be realized from day one.

• Additional synergies from market expansion and professionalized forecasting.